Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia

Experimental and Therapeutic Medicine

Volumn 8, Issue 6, 2014, Pages 1737-1744

  Ding, Mei ^a   Si, Daoyuan ^a   Zhang, Wenqi ^a   Feng, Zhaohui ^a   He, Min ^a   Yang, Ping ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Hyperlipidimia; Interleukin 6; Kidney function; Tumor necrosis factor ; Xuezhikang

Indexed keywords

CATALASE; CHOLESTEROL; CREATININE; GLUCOSE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLAMMATORY TRANSCRIPTION FACTOR; INTERLEUKIN 6; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MESSENGER RNA; MEVINOLIN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URIC ACID; XUEZHIKANG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DOWN REGULATION; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SPECTROPHOTOMETER; UPREGULATION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

EID: 84908201160     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.2035     Document Type: Article

References (36)

1. Suk HY, Zhou C, Yang TT, et al: Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases. J Biol Chem 288: 3477-3488, 2013.
2. Pöss J, Custodis F, Werner C, Weingärtner O, Böhm M and Laufs U: Cardiovascular disease and dyslipidemia: beyond LDL. Curr Pharm Des 17: 861-870, 2011.
3. Vaziri ND and Norris K: Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 31: 189-196, 2011.
4. Burst V and Benzing T: Dyslipidemia treatment and cardiovascular disease in the renal patient. Curr Pharm Des 17: 894-907, 2011.
5. Lu ZL, Xu ZM, Kou WR and Zhao SP: Advance in basic and clinical research of Xuezhikang capsule. Chin J Integr Med 12: 85-93, 2006.
6. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, et al: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829-1839, 2007.
7. Shang Q, Liu Z, Chen K, Xu H and Liu J: A systematic review of Xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012: 636547, 2012.
8. Ma J, Li Y, Ye Q, et al: Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48: 5220-5225, 2000.
9. Zhu XY, Li P, Yang YB and Liu ML: Xuezhikang, extract of red yeast rice, improved abnormal hemorheology, suppressed caveolin-1 and increased eNOS expression in atherosclerotic rats. PLoS One 8: e62731, 2013.
10. Journoud M and Jones PJ: Red yeast rice: a new hypolipidemic drug. Life Sci 74: 2675-2683, 2004.
11. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T and Fønnebø V: Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 1: 4, 2006.
12. Lu Z, Kou W, Du B, et al; Chinese Coronary Secondary Prevention Study Group: Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101: 1689-1693, 2008.
13. Hong XZ, Li LD and Wu LM: Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 34: 27-35, 2007.
14. Aebi H: Catalase in vitro. Methods Enzymol 105: 121-126, 1984.
15. Paglia DE and Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169, 1967.
16. Pan D, Zhang D, Wu J, et al: A novel proteoglycan from Ganoderma lucidum fruiting bodies protects kidney function and ameliorates diabetic nephropathy via its antioxidant activity in C57BL/6 db/db mice. Food Chem Toxicol 63: 111-118, 2014.
17. Tietge UJ: Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol 25: 94-95, 2014.
18. Martin SS, Blaha MJ, Blankstein R, et al: Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation 129: 77-86, 2014.
19. Schaeffner ES, Kurth T, Curhan GC, et al: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084-2091, 2003.
20. Mänttäri M, Tiula E, Alikoski T and Manninen V: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26: 670-675, 1995.
21. Takemura T, Yoshioka K, Aya N, et al: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 43: 918-927, 1993.
22. Abrass CK: Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24: 46-53, 2004.
23. Tonelli M, Moyé L, Sacks FM, et al; Cholesterol and Recurrent Events Trial Investigators: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613, 2003.
24. Peev V, Nayer A and Contreras G: Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. Curr Opin Lipidol 25: 54-60, 2014.
25. Shi Y, Guo R, Wang X, et al: The regulation of alfalfa saponin extract on key genes involved in hepatic cholesterol metabolism in hyperlipidemic rats. PLoS One 9: e88282, 2014.
26. Arafa HM: Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Monit 11: BR228-BR234, 2005.
27. Martin SS, Blaha MJ, Blankstein R, et al: Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation 129: 77-86, 2014.
28. Tolman KG: The liver and lovastatin. Am J Cardiol 89: 1374-1380, 2002.
29. Campese VM: Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clin Exp Nephrol 18: 291-295, 2014.
30. Shang Q, Liu Z, Chen K, Xu H and Liu J: A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012: 636547, 2012.
31. Lin YC, Chiang CH, Chang LT, et al: Simvastatin attenuates the additive effects of TNF-α and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Cytokine 62: 341-351, 2013.
32. Li Z, Yang S, Lin H, et al: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37: 343-350, 2003.
33. Libby P, Sukhova G, Lee RT and Galis ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25 (Suppl 2): S9-S12, 1995.
34. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
35. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL and Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89: 4845-4849, 1992.
36. Fan XF, Deng YQ, Ye L, et al: Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J Integr Med 16: 119-123, 2010.